Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer Who Failed From First Line PD-(L)-1 Inhibitors: Multiple Cohorts Perspective Study

Next Previous
Trial Profile

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer Who Failed From First Line PD-(L)-1 Inhibitors: Multiple Cohorts Perspective Study

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 322 (Primary) ; Lenvatinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BELIEVE

Most Recent Events

  • 25 Dec 2023 Planned End Date changed from 25 Dec 2024 to 25 Dec 2025.
  • 25 Dec 2023 Status changed from not yet recruiting to recruiting.
  • 08 Sep 2023 Planned initiation date changed from 1 Aug 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top